Alaunos Therapeutics (TCRT) Competitors $2.48 -0.19 (-7.12%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$2.41 -0.07 (-2.82%) As of 04/17/2025 05:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock TCRT vs. QTTB, ANVS, JATT, CDIO, CVM, LSTA, LSB, UBX, NNVC, and EQShould you be buying Alaunos Therapeutics stock or one of its competitors? The main competitors of Alaunos Therapeutics include Q32 Bio (QTTB), Annovis Bio (ANVS), JATT Acquisition (JATT), Cardio Diagnostics (CDIO), CEL-SCI (CVM), Lisata Therapeutics (LSTA), Lakeshore Biopharma (LSB), Unity Biotechnology (UBX), NanoViricides (NNVC), and Equillium (EQ). These companies are all part of the "pharmaceutical products" industry. Alaunos Therapeutics vs. Q32 Bio Annovis Bio JATT Acquisition Cardio Diagnostics CEL-SCI Lisata Therapeutics Lakeshore Biopharma Unity Biotechnology NanoViricides Equillium Alaunos Therapeutics (NASDAQ:TCRT) and Q32 Bio (NASDAQ:QTTB) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, dividends, risk, institutional ownership, profitability, community ranking, analyst recommendations, valuation and media sentiment. Which has stronger earnings & valuation, TCRT or QTTB? Alaunos Therapeutics has higher revenue and earnings than Q32 Bio. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlaunos Therapeutics$10K397.05-$35.14MN/AN/AQ32 Bio-$6.65M-3.89-$112.96M-$10.37-0.20 Does the MarketBeat Community favor TCRT or QTTB? Q32 Bio received 5 more outperform votes than Alaunos Therapeutics when rated by MarketBeat users. Likewise, 63.16% of users gave Q32 Bio an outperform vote while only 58.33% of users gave Alaunos Therapeutics an outperform vote. CompanyUnderperformOutperformAlaunos TherapeuticsOutperform Votes758.33% Underperform Votes541.67% Q32 BioOutperform Votes1263.16% Underperform Votes736.84% Does the media refer more to TCRT or QTTB? In the previous week, Q32 Bio had 2 more articles in the media than Alaunos Therapeutics. MarketBeat recorded 2 mentions for Q32 Bio and 0 mentions for Alaunos Therapeutics. Alaunos Therapeutics' average media sentiment score of 0.00 equaled Q32 Bio'saverage media sentiment score. Company Overall Sentiment Alaunos Therapeutics Neutral Q32 Bio Neutral Which has more risk & volatility, TCRT or QTTB? Alaunos Therapeutics has a beta of -0.74, suggesting that its share price is 174% less volatile than the S&P 500. Comparatively, Q32 Bio has a beta of -0.17, suggesting that its share price is 117% less volatile than the S&P 500. Do analysts rate TCRT or QTTB? Q32 Bio has a consensus price target of $24.71, suggesting a potential upside of 1,065.77%. Given Q32 Bio's stronger consensus rating and higher probable upside, analysts clearly believe Q32 Bio is more favorable than Alaunos Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alaunos Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Q32 Bio 0 Sell rating(s) 6 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Is TCRT or QTTB more profitable? Q32 Bio's return on equity of -146.18% beat Alaunos Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Alaunos TherapeuticsN/A -267.77% -209.18% Q32 Bio N/A -146.18%-54.49% Do institutionals & insiders have more ownership in TCRT or QTTB? 27.7% of Alaunos Therapeutics shares are owned by institutional investors. Comparatively, 31.3% of Q32 Bio shares are owned by institutional investors. 5.1% of Alaunos Therapeutics shares are owned by insiders. Comparatively, 16.1% of Q32 Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. SummaryQ32 Bio beats Alaunos Therapeutics on 11 of the 14 factors compared between the two stocks. Get Alaunos Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TCRT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TCRT vs. The Competition Export to ExcelMetricAlaunos TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.97M$6.44B$5.30B$7.35BDividend YieldN/A3.20%5.45%4.30%P/E RatioN/A6.8921.8617.81Price / Sales397.05230.51380.6697.70Price / CashN/A65.6738.2634.64Price / Book0.635.936.453.98Net Income-$35.14M$142.99M$3.22B$247.81M1 Month Performance72.22%-13.56%-9.75%-7.92%1 Year Performance-77.86%-8.89%11.50%1.52% Alaunos Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TCRTAlaunos Therapeutics0.6771 of 5 stars$2.48-7.1%N/A-79.8%$3.97M$10,000.000.0040Gap DownQTTBQ32 Bio1.7956 of 5 stars$1.52-1.0%$24.71+1,531.3%-91.3%$18.79M$-6,651,000.00-0.1139News CoveragePositive NewsGap UpANVSAnnovis Bio1.4763 of 5 stars$1.27+2.0%$37.00+2,824.9%-87.4%$18.01MN/A-0.283Gap UpJATTJATT AcquisitionN/A$1.03-5.1%N/A-60.7%$17.77MN/A0.003High Trading VolumeCDIOCardio Diagnostics1.8004 of 5 stars$0.34+4.5%$2.00+484.8%-64.2%$17.73M$34,890.000.001Short Interest ↑Negative NewsCVMCEL-SCIN/A$0.22+3.5%N/A-83.2%$17.30MN/A-0.4543Gap UpLSTALisata Therapeutics2.003 of 5 stars$2.00+5.0%$15.00+651.9%-20.7%$17.20M$1M-0.7930News CoveragePositive NewsLSBLakeshore Biopharma0.499 of 5 stars$1.83-6.4%N/AN/A$16.98M$672.27M0.00773Short Interest ↑Gap UpUBXUnity Biotechnology3.7236 of 5 stars$1.00+8.3%$5.33+432.3%-35.8%$16.95M$240,000.00-0.7760Upcoming EarningsNNVCNanoViricidesN/A$1.06+1.9%N/A+13.7%$16.58MN/A-1.4720EQEquillium3.0517 of 5 stars$0.46+2.8%$3.00+546.6%-72.7%$16.56M$41.10M-3.3240Short Interest ↓Positive NewsGap Up Related Companies and Tools Related Companies Q32 Bio Alternatives Annovis Bio Alternatives JATT Acquisition Alternatives Cardio Diagnostics Alternatives CEL-SCI Alternatives Lisata Therapeutics Alternatives Lakeshore Biopharma Alternatives Unity Biotechnology Alternatives NanoViricides Alternatives Equillium Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TCRT) was last updated on 4/19/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredThe Crypto Market is About to Change LivesI've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alaunos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alaunos Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy TCRT Stock Free TCRT Stock Alerts